The ethnic profile of triple-negative breast cancer

Onkologie

Volumn 31, Issue 11, 2008, Pages 580-582

  Cleator, Susan J ^a   Palmieri, Carlo ^b   Coombes, Charles R ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASIAN; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; EDITORIAL; ETHNICITY; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; PHENOTYPE; TRIPLE NEGATIVE BREAST CANCER;

AGE DISTRIBUTION; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; FEMALE; HUMANS; PREVALENCE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS;

EID: 58849098671     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000164270     Document Type: Editorial

References (25)

1. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q: Clinicopathologic and prognostic characteristics of triple negative breast cancer. Onkologie 2008;31:610-614.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423.
4. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350.
5. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
6. Lamovec J, Us-Krasovec M, Zidar A, Kljun A: Adenoid cystic carcinoma of the breast: a histologic, cytologic, and immunohistochemical study. Semin Diagn Pathol 1989;6:153-164.
7. Tot T: The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000;37:175-181.
8. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539.
9. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
10. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C, Rosty C, Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sastre-Garau X, Vincent-Salomon A: KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005;18:1623-1631.
11. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
12. Carey A, Dees C, Sawyer L, Gatti L, Moore D, Collichio F, Ollila D, Sartor C, Graham M, Perou C: The triple negative paradox: primary tumour chemosensitivity of breast cancer subtypes. Clinical Cancer Research 2007;13:2329-2334.
13. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, Isola J: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007;9:R16.
14. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9:R30.
15. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161.
16. Nelson N: Migrant Studies Aid the Search for Factor Linked in Breast Cancer Risk. JNCI 2006:436-338.
17. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
18. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-884.
19. Olopade OI, Ikpatt F, Perou CM: Intrinsic Gene Expression subtypes correlated with grade andmorphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. ASCO 2004:abstr 9509.
20. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
21. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-139.
22. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-1226.
23. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K: The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007;16(Suppl 2):S72-S77.
24. Parkin D, Whelan S, Ferley J, Storm H: Cancer Incidence in Five Continents. Lyon, IARC Cancer Base, 2005.
25. Leung G, Thach T, Lam T: Trends in breast cancer incidence in Hong Kong between 1973 and 1999: and age-period-cohort analysis. Br J Cancer 2002;97:982-988.